These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 23936095

  • 1. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
    McCaughey G, Diamond P, Elborn JS, McKevitt M, Tunney MM.
    PLoS One; 2013; 8(7):e69763. PubMed ID: 23936095
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G, McKevitt M, Elborn JS, Tunney MM.
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [Abstract] [Full Text] [Related]

  • 3. Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
    McCaughey G, Gilpin DF, Schneiders T, Hoffman LR, McKevitt M, Elborn JS, Tunney MM.
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5406-14. PubMed ID: 23959314
    [Abstract] [Full Text] [Related]

  • 4. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M, Morosini MI, Köksal E, Oliver A, Ekkelenkamp M, Cantón R.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [Abstract] [Full Text] [Related]

  • 5. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR, White A, Elborn JS, Tunney MM.
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
    [Abstract] [Full Text] [Related]

  • 6. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, Macleod C, Aaron SD, Harbour C.
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [Abstract] [Full Text] [Related]

  • 7. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
    King P, Citron DM, Griffith DC, Lomovskaya O, Dudley MN.
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations.
    Díez-Aguilar M, Morosini MI, Tedim AP, Rodríguez I, Aktaş Z, Cantón R.
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6039-45. PubMed ID: 26195514
    [Abstract] [Full Text] [Related]

  • 9. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
    MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns JL, Baker WR.
    J Antimicrob Chemother; 2009 Oct; 64(4):829-36. PubMed ID: 19679597
    [Abstract] [Full Text] [Related]

  • 10. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
    Valenza G, Radike K, Schoen C, Horn S, Oesterlein A, Frosch M, Abele-Horn M, Hebestreit H.
    Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333
    [Abstract] [Full Text] [Related]

  • 11. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
    Law JP, Wood AJ, Friman VP.
    Microbiol Spectr; 2022 Dec 21; 10(6):e0184222. PubMed ID: 36453898
    [Abstract] [Full Text] [Related]

  • 12. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC, Landersdorfer CB, McIntosh MP, Peleg AY, Hirsch EB, Kirkpatrick CM, Bergen PJ.
    J Antimicrob Chemother; 2016 Aug 21; 71(8):2218-29. PubMed ID: 27118778
    [Abstract] [Full Text] [Related]

  • 13. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Breen SKJ, Harper M, López-Causapé C, Rogers KE, Tait JR, Smallman TR, Lang Y, Lee WL, Zhou J, Zhang Y, Bulitta JB, Nation RL, Oliver A, Boyce JD, Landersdorfer CB.
    Int J Antimicrob Agents; 2024 Jun 21; 63(6):107161. PubMed ID: 38561094
    [Abstract] [Full Text] [Related]

  • 14. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
    Furiga A, Lajoie B, El Hage S, Baziard G, Roques C.
    Antimicrob Agents Chemother; 2015 Dec 28; 60(3):1676-86. PubMed ID: 26711774
    [Abstract] [Full Text] [Related]

  • 15. Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.
    Anderson GG, Kenney TF, Macleod DL, Henig NR, O'Toole GA.
    Pathog Dis; 2013 Feb 28; 67(1):39-45. PubMed ID: 23620118
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T, Petrova G, Mitov I.
    J Chemother; 2010 Dec 28; 22(6):378-83. PubMed ID: 21303744
    [Abstract] [Full Text] [Related]

  • 17. Prevalence of fosfomycin resistance and gene mutations in clinical isolates of methicillin-resistant Staphylococcus aureus.
    Lee YC, Chen PY, Wang JT, Chang SC.
    Antimicrob Resist Infect Control; 2020 Aug 17; 9(1):135. PubMed ID: 32807239
    [Abstract] [Full Text] [Related]

  • 18. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa.
    MacLeod DL, Velayudhan J, Kenney TF, Therrien JH, Sutherland JL, Barker LM, Baker WR.
    Antimicrob Agents Chemother; 2012 Mar 17; 56(3):1529-38. PubMed ID: 22232284
    [Abstract] [Full Text] [Related]

  • 19. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.
    Rodríguez-Rojas A, Maciá MD, Couce A, Gómez C, Castañeda-García A, Oliver A, Blázquez J.
    PLoS One; 2010 Apr 15; 5(4):e10193. PubMed ID: 20419114
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis.
    Champion EA, Miller MB, Popowitch EB, Hobbs MM, Saiman L, Muhlebach MS, STAR-CF Study Team.
    Pediatr Pulmonol; 2014 Mar 15; 49(3):230-7. PubMed ID: 23765686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.